Current therapy of chronic hepatitis C infection

M. E. Viernes, T. J. Byrne, J. G. McHutchison

Research output: Contribution to journalArticle

Abstract

Hepatitis C (HCV) is a major cause of end stage liver disease worldwide and a leading indication for liver transplantation. Current treatments can eradicate the virus and improve liver histology in certain patients. The current most efficacious treatment for patients with HCV is interferon combined with ribavirin, which eradicates the virus long-term in 35-40% of treated patients. For those in whom ribavirin is contraindicated, interferon alone may be used with successful viral eradication in approximately 15% of patients. Herein, we will discuss the current recommended initial treatment, indications and contraindications to therapy, workup and monitoring of patients during and after therapy, the side effects associated with treatment, the predictors of response, and the therapy response. Finally, we will discuss potential future treatment regimens that may lead to improved efficacy in the management of chronic HCV patients.

Original languageEnglish (US)
Pages (from-to)14-21+25
JournalPractical Gastroenterology
Volume25
Issue number7
StatePublished - 2001
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Infection
Ribavirin
Therapeutics
Interferons
Viruses
End Stage Liver Disease
Physiologic Monitoring
Hepatitis C
Liver Transplantation
Histology
Liver

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Viernes, M. E., Byrne, T. J., & McHutchison, J. G. (2001). Current therapy of chronic hepatitis C infection. Practical Gastroenterology, 25(7), 14-21+25.

Current therapy of chronic hepatitis C infection. / Viernes, M. E.; Byrne, T. J.; McHutchison, J. G.

In: Practical Gastroenterology, Vol. 25, No. 7, 2001, p. 14-21+25.

Research output: Contribution to journalArticle

Viernes, ME, Byrne, TJ & McHutchison, JG 2001, 'Current therapy of chronic hepatitis C infection', Practical Gastroenterology, vol. 25, no. 7, pp. 14-21+25.
Viernes ME, Byrne TJ, McHutchison JG. Current therapy of chronic hepatitis C infection. Practical Gastroenterology. 2001;25(7):14-21+25.
Viernes, M. E. ; Byrne, T. J. ; McHutchison, J. G. / Current therapy of chronic hepatitis C infection. In: Practical Gastroenterology. 2001 ; Vol. 25, No. 7. pp. 14-21+25.
@article{7d75c9b053764481ae73854e6be0c824,
title = "Current therapy of chronic hepatitis C infection",
abstract = "Hepatitis C (HCV) is a major cause of end stage liver disease worldwide and a leading indication for liver transplantation. Current treatments can eradicate the virus and improve liver histology in certain patients. The current most efficacious treatment for patients with HCV is interferon combined with ribavirin, which eradicates the virus long-term in 35-40{\%} of treated patients. For those in whom ribavirin is contraindicated, interferon alone may be used with successful viral eradication in approximately 15{\%} of patients. Herein, we will discuss the current recommended initial treatment, indications and contraindications to therapy, workup and monitoring of patients during and after therapy, the side effects associated with treatment, the predictors of response, and the therapy response. Finally, we will discuss potential future treatment regimens that may lead to improved efficacy in the management of chronic HCV patients.",
author = "Viernes, {M. E.} and Byrne, {T. J.} and McHutchison, {J. G.}",
year = "2001",
language = "English (US)",
volume = "25",
pages = "14--21+25",
journal = "Practical Gastroenterology",
issn = "0277-4208",
publisher = "Shugar Publishing Inc.",
number = "7",

}

TY - JOUR

T1 - Current therapy of chronic hepatitis C infection

AU - Viernes, M. E.

AU - Byrne, T. J.

AU - McHutchison, J. G.

PY - 2001

Y1 - 2001

N2 - Hepatitis C (HCV) is a major cause of end stage liver disease worldwide and a leading indication for liver transplantation. Current treatments can eradicate the virus and improve liver histology in certain patients. The current most efficacious treatment for patients with HCV is interferon combined with ribavirin, which eradicates the virus long-term in 35-40% of treated patients. For those in whom ribavirin is contraindicated, interferon alone may be used with successful viral eradication in approximately 15% of patients. Herein, we will discuss the current recommended initial treatment, indications and contraindications to therapy, workup and monitoring of patients during and after therapy, the side effects associated with treatment, the predictors of response, and the therapy response. Finally, we will discuss potential future treatment regimens that may lead to improved efficacy in the management of chronic HCV patients.

AB - Hepatitis C (HCV) is a major cause of end stage liver disease worldwide and a leading indication for liver transplantation. Current treatments can eradicate the virus and improve liver histology in certain patients. The current most efficacious treatment for patients with HCV is interferon combined with ribavirin, which eradicates the virus long-term in 35-40% of treated patients. For those in whom ribavirin is contraindicated, interferon alone may be used with successful viral eradication in approximately 15% of patients. Herein, we will discuss the current recommended initial treatment, indications and contraindications to therapy, workup and monitoring of patients during and after therapy, the side effects associated with treatment, the predictors of response, and the therapy response. Finally, we will discuss potential future treatment regimens that may lead to improved efficacy in the management of chronic HCV patients.

UR - http://www.scopus.com/inward/record.url?scp=0034909271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034909271&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 14-21+25

JO - Practical Gastroenterology

JF - Practical Gastroenterology

SN - 0277-4208

IS - 7

ER -